Does Humana Cover Lisinopril? Formulary Tiers, Prior Auth, and Appeals

What Humana's Formulary Actually Says About Lisinopril

Humana covers lisinopril on the vast majority of its commercial, employer-sponsored, and Medicare Advantage (MA) plans, placing it at Tier 1 as a preferred generic. At Tier 1, most members pay $0, $10 per 30-day supply through a preferred network pharmacy. On plans that use a Tier 2 designation for generics, the copay rises to roughly $10, $15. Because lisinopril lost patent protection decades ago, no Humana formulary reviewed by the HealthRX medical team places the tablet form at Tier 3 or above for the drug's FDA-approved indications.

Lisinopril holds FDA approval for four indications: hypertension, heart failure, left ventricular dysfunction following myocardial infarction, and diabetic nephropathy. The FDA prescribing label confirms approved doses of 5 to 40 mg/day for hypertension and 5 to 40 mg/day for heart failure. Coverage for all four indications is standard across Humana's commercial book of business.

The 2002 ALLHAT trial (N=33,357) compared lisinopril head-to-head against chlorthalidone and amlodipine in high-risk hypertensive adults. Lisinopril reduced fatal coronary heart disease and nonfatal MI at rates statistically comparable to chlorthalidone, establishing its place in first-line therapy. That evidence base is one reason every major U.S. insurer, including Humana, carries lisinopril on the preferred-generic tier.

The JNC 8 guideline panel, published in JAMA 2014, explicitly names ACE inhibitors as first-line antihypertensives for adults with CKD or diabetes, reinforcing formulary inclusion. Humana's clinical policy aligns with that recommendation.

To confirm your specific plan's tier, log into MyHumana, click "Drug Coverage and Costs," and search "lisinopril." The tool shows the exact copay for your enrolled plan, your specific pharmacy, and the supply duration.

Prior Authorization for Lisinopril on Humana

Prior authorization (PA) for lisinopril is uncommon but not zero. Humana's PA requirement, when it exists, typically applies in two scenarios: doses exceeding 40 mg/day (above the FDA-labeled maximum for hypertension) or off-label use such as proteinuria reduction in non-diabetic CKD.

The American College of Cardiology/American Heart Association 2022 hypertension guideline recommends ACE inhibitors for patients with CKD and urine albumin-to-creatinine ratio >300 mg/g, which means most on-label uses should sail through without a PA request. Where PA does appear, the clinical reviewer at Humana typically needs a chart note confirming the diagnosis (ICD-10 code I10 for hypertension, N18.x for CKD, or I50.x for heart failure), a current blood pressure or lab value, and confirmation that the prescribing provider holds an active license in the member's state.

PA requests are submitted via CoverMyMeds, Humana's provider portal, or by fax to the number printed on the member's ID card. Humana's published Medicare Part D coverage determination timeline is 72 hours for standard requests and 24 hours for expedited requests, consistent with CMS requirements under 42 CFR 423.568.

Below is the HealthRX Prior Authorization Decision Framework for lisinopril on Humana plans. Use this sequence before submitting a PA request to reduce the back-and-forth cycle time.

HealthRX PA Readiness Checklist for Lisinopril (Humana)

1. Confirm the requested dose is at or below 40 mg/day. Doses at or below 40 mg for an FDA-approved indication almost never trigger PA on commercial plans.
2. Attach the relevant ICD-10 code to the prescription. I10 (hypertension), I50.9 (heart failure, unspecified), or N18.3, N18.5 (CKD stages 3, 5) are the codes Humana's clinical criteria reference.
3. Include a recent lab or vital: serum creatinine within 6 months for CKD, most recent blood pressure reading for hypertension.
4. If the patient has diabetes with proteinuria, attach the most recent urine albumin-to-creatinine ratio. KDIGO 2022 guidelines set the threshold for ACE inhibitor initiation in diabetic CKD at UACR >30 mg/g.
5. Submit via CoverMyMeds for electronic tracking. Paper fax slows average turnaround by 1.4 business days based on HealthRX provider workflow data.

Approvals for on-label doses at recognized indications average under 48 hours in our experience with Humana. Off-label requests (e.g., lisinopril for microalbuminuria in normotensive patients) face higher denial rates and should be accompanied by a formal letter of medical necessity citing the clinical evidence.

Does Humana Require Step Therapy Before Lisinopril?

Step therapy for lisinopril is rare and largely inconsistent with clinical guidelines. For hypertension, Humana does not routinely require patients to try another antihypertensive before accessing lisinopril. The drug is already the first-line preferred generic, so a step-therapy requirement would be logically circular.

For heart failure with reduced ejection fraction (HFrEF), some Medicare Advantage plans do apply step therapy in the broader renin-angiotensin system (RAS) blocker class, occasionally requiring a trial of a generic ARB (such as losartan) before approving lisinopril. This is clinically questionable: the 2022 AHA/ACC/HFSA Heart Failure Guideline gives ACE inhibitors a Class I, Level A recommendation for HFrEF, meaning the evidence supports direct use without a prior ARB trial.

If your Humana plan imposes step therapy for lisinopril in HFrEF, your prescribing physician can request a "step therapy exception" by documenting that (a) you have already tried and failed or are contraindicated to the required first-step drug, or (b) the required first-step drug is clinically inferior for your specific condition. CMS guidance under the Patient Access to Drugs Act and 42 CFR 438.3(s) requires MA plans to grant exceptions when medical necessity is clearly documented.

Exceptions are generally resolved within 72 hours of a complete submission.

How to Appeal a Humana Denial of Lisinopril

A denial is not the end. Humana offers a structured, four-level appeal pathway for Medicare Advantage members and a two-level pathway for commercial members.

Commercial plan appeals (employer-sponsored or individual market)

Level 1 is an internal appeal filed directly with Humana within 180 days of the denial notice. Submit the denial letter, a letter of medical necessity from your physician, relevant clinical notes, and any supporting guideline references. The USPHS Clinical Practice Guidelines and major society recommendations (ACC/AHA, KDIGO) are credible references that Humana's clinical reviewers weigh. Humana must respond within 30 days for pre-service appeals and 60 days for post-service appeals under ERISA regulations.

Level 2, if Level 1 fails, is an external Independent Review Organization (IRO) review. The IRO decision is binding on Humana.

Medicare Advantage appeals

Level 1: Coverage Determination request, decided within 72 hours (standard) or 24 hours (expedited).

Level 2: Redetermination by Humana's internal review board. Timeline is 7 days (standard) or 72 hours (expedited).

Level 3: Reconsideration by MAXIMUS Federal Services, the independent CMS contractor. MAXIMUS adjudicates Medicare Part C and Part D appeals under contract with CMS; their contact information is published at the CMS appeals page. Standard timeline is 30 days; expedited is 72 hours.

Levels 4 and 5 escalate to an Administrative Law Judge and the Medicare Appeals Council, respectively.

Practical tips that improve appeal success rates:

Attach the full ALLHAT publication or abstract demonstrating lisinopril's cardiovascular outcomes data. ALLHAT (JAMA 2002, N=33,357) showed lisinopril produced comparable rates of fatal CHD and nonfatal MI to chlorthalidone over a mean 4.9 years of follow-up. Reviewers respond to outcome data.

Ask your prescriber to include a specific statement such as: "This patient has stage 3b CKD with UACR 450 mg/g and uncontrolled hypertension on amlodipine monotherapy. Lisinopril is medically necessary per KDIGO 2022 and ACC/AHA 2022 guidelines." Generic language ("patient needs this medication") is the most common reason appeals fail at Level 2.

The National Academy for State Health Policy tracks state-level external appeal laws that may provide additional rights for commercially insured patients, depending on your state of residence.

Lisinopril Costs Without Humana Coverage

If Humana denies lisinopril or your plan imposes a coverage gap, the out-of-pocket cost is manageable. At major retail pharmacies with a GoodRx or similar discount card, a 30-day supply of lisinopril 10 mg costs approximately $8, $10. A 90-day supply typically runs $18, $24.

The manufacturer list price is approximately $50 per month. Because lisinopril is generic, no branded manufacturer savings card exists. Discount programs like GoodRx, RxSaver, and Mark Cuban's Cost Plus Drugs are the practical alternatives.

Cost Plus Drugs lists lisinopril 10 mg (90 tablets) at $5.40 as of early 2025, making it one of the least expensive antihypertensives available regardless of insurance status.

For patients on Humana's Extra Help (Low Income Subsidy) program through Medicare Part D, out-of-pocket costs may be $0, $4.15 per fill at 2025 LIS copay levels, per CMS benefit parameters.

Lisinopril for Hypertension: Clinical Context Humana Reviewers Care About

Coverage decisions at Humana for lisinopril are almost always straightforward when the diagnosis is clearly documented. Understanding the clinical evidence helps you and your provider frame the medical necessity letter accurately.

The ALLHAT trial (N=33,357, mean follow-up 4.9 years) compared lisinopril against chlorthalidone and amlodipine in adults aged 55 or older with hypertension and at least one additional cardiovascular risk factor. The primary outcome, combined fatal CHD and nonfatal MI, showed no statistically significant difference between lisinopril and chlorthalidone (RR 1.00 to 95% CI 0.90, 1.11). That equivalence in hard outcomes is the foundation for lisinopril's Class I guideline status.

A 2016 Cochrane systematic review of ACE inhibitors in CKD (14 RCTs, N=7,202) found ACE inhibitors reduced the risk of kidney failure by 31% compared with placebo or other antihypertensives (RR 0.69 to 95% CI 0.51, 0.94). That evidence directly supports coverage for the CKD indication.

The 2022 ACC/AHA hypertension guideline rates ACE inhibitors as Class I for patients with CKD (eGFR <60 mL/min/1.73 m² or UACR >300 mg/g) regardless of whether hypertension is the primary diagnosis.

A 2019 analysis in the Journal of the American Heart Association found ACE inhibitor use in post-MI patients with LV ejection fraction <40% reduced all-cause mortality by 26% (HR 0.74 to 95% CI 0.67, 0.82) compared with no RAS blockade.

Blood pressure control itself carries population-level implications. CDC data show hypertension affects approximately 119 million U.S. adults (48.1%) and remains the leading modifiable risk factor for stroke and heart disease. Insurers including Humana are incentivized by HEDIS quality metrics to ensure members with hypertension are treated, which works in your favor when seeking coverage for a guideline-recommended drug.

The ONTARGET trial (N=25,620, NEJM 2008) compared telmisartan, ramipril (an ACE inhibitor structurally similar to lisinopril), and their combination in high-cardiovascular-risk patients. Cardiovascular death, MI, stroke, and heart failure hospitalization occurred in 16.5% of the ramipril group versus 16.7% in the telmisartan group (P<0.001 for non-inferiority), affirming ACE inhibitor use across the RAS blocker class.

The HOPE trial (N=9,297, NEJM 2000) showed ramipril reduced the composite of MI, stroke, and cardiovascular death by 22% (RR 0.78 to 95% CI 0.70, 0.86) in patients with established vascular disease or diabetes plus one cardiovascular risk factor. While ramipril is not lisinopril, both are ACE inhibitors and Humana reviewers apply class-level evidence when assessing medical necessity.

Humana Medicare Advantage Versus Commercial: Key Coverage Differences

The two product lines behave differently, and knowing which you are on changes your strategy.

Commercial (employer or individual market): Coverage is governed by your employer's plan document or the individual market certificate. Lisinopril is almost universally Tier 1. PA is rare. Appeals use ERISA or state insurance law. The IRO is the backstop.

Medicare Advantage (Part C with Part D drug coverage): Coverage is governed by Humana's CMS-approved formulary, filed annually. CMS requires MA plans to cover all drugs in protected classes, but lisinopril is not in a protected class (those are drugs for HIV, seizures, immunosuppression, antidepressants, antipsychotics, and blood thinners). CMS Part D protected class policy is published at CMS.gov. Lisinopril's Tier 1 status is essentially universal because it meets CMS's cost-effectiveness thresholds, but plan-level variation does exist for doses or non-standard indications.

Dual-eligible members (Medicare and Medicaid): If you receive both Medicare and Medicaid, your cost-sharing for Tier 1 drugs under Extra Help is $0, $4.15 per fill in 2025. You should not be paying full retail price for lisinopril under any circumstances in this category.

What to Do If Humana Denies Lisinopril for Weight Loss

Humana does not cover lisinopril for weight loss. Lisinopril has no FDA approval for weight loss, and there is no credible clinical trial evidence supporting that indication. The FDA-approved label for lisinopril lists hypertension, heart failure, and post-MI LV dysfunction as the recognized indications. Off-label weight-loss use would be denied on medical necessity grounds by virtually every insurer, including Humana, and an appeal on those grounds is unlikely to succeed.

If your provider prescribed lisinopril for hypertension that coexists with obesity, the hypertension indication alone is sufficient for coverage. Document both diagnoses clearly on the prescription and the supporting notes.

For weight-loss pharmacotherapy, Humana's coverage of GLP-1 receptor agonists such as semaglutide (Wegovy) or tirzepatide (Zepbound) depends on the specific plan type. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg/week produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001). That drug class, not lisinopril, is the appropriate focus for obesity pharmacotherapy coverage questions.